Nicholas Boston
@Highvista Strategies Llc
Latest period2024 - Q3ReportedManaged Assets$289.961MTotal holdings142
Assets growth rate5.92%Assets growth rate (2-Q avg)1.78%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Highvista Strategies Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 142 positions.
Assets under management
The assets under management (AUM) of Highvista Strategies Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 289.961M in assets, with a quarterly growth rate of 5.92% and a 2-quarter average growth rate of 1.78%. The portfolio is managed by Nicholas Boston, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
DNTHDianthus Therapeutics Inc
| 0.19% | $542,343 19,808 shares@ $27.38 avg price | New Position |
CGEMCullinan Therapeutics Inc
| 0.19% | $533,889 31,893 shares@ $16.75 avg price | New Position |
CYTKCytokinetics Inc
| 0.19% | $530,904 10,055 shares@ $52.8 avg price | New Position |
ANABAnaptysbio Inc
| 0.18% | $521,729 15,574 shares@ $33.5 avg price | New Position |
ETNB89bio Inc
| 0.18% | $494,224 66,787 shares@ $7.41 avg price | New Position |
URGNUrogen Pharma Ltd
| 0.17% | $489,788 38,566 shares@ $12.7 avg price | New Position |
IRONDisc Medicine Inc
| 0.17% | $470,024 9,565 shares@ $49.14 avg price | New Position |